DUBLIN--(BUSINESS WIRE)--The "Cell Wall Synthesis Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
This Cell Wall Synthesis Inhibitors - Pipeline Insight, 2021 report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Cell Wall Synthesis Inhibitors pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Cell Wall Synthesis Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Cell Wall Synthesis Inhibitors.
Cell Wall Synthesis Inhibitors Emerging Drugs Chapters
This segment of the Cell Wall Synthesis Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cell Wall Synthesis Inhibitors Emerging Drugs
Tebipenem HBr: Spero Therapeutics
Tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994) is an oral antibiotic for the treatment of complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) to help patients avoid hospitalizations (stay at home) and/or transition patient's home after IV therapy (get home). ebipenem HBr has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the FDA for the treatment of cUTI and AP. Spero expects to submit a New Drug Application to the U.S. Food and Drug Administration (FDA) for tebipenem HBr in the second half of 2021. If approved, tebipenem HBr would be the first oral carbapenem to receive marketing approval in the United States.
Taniborbactam: VenatoRx Pharmaceuticals
Taniborbactam (formerly VNRX-5133), an injectable beta-lactamase inhibitor (BLI) that features selective and potent in vitro activity against both serine- and metallo-beta-lactamases (MBLs), including the following enzymes: extended spectrum beta-lactamase (ESBL); Oxacillinase (OXA); Klebsiella pneumoniae carbapenemase (KPC); New Delhi metallo-beta-lactamase (NDM); and Verona integron-encoded metallo-beta-lactamase (VIM). Venatorx is currently enrolling a Phase 3 clinical trial of cefepime-taniborbactam in patients with complicated urinary tract infections (cUTIs).
VNRX-7145: VenatoRx Pharmaceuticals
VNRX-7145, an orally bioavailable beta-lactamase inhibitor (BLI) that in a fixed combination with the third generation orally bioavailable cephalosporin, ceftibuten, has the potential to rescue activity of the partner antibiotic against extended spectrum beta-lactamases (ESBLs) and key carbapenem-resistant Enterobacterales (CRE), including those expressing Klebsiella pneumoniae carbapenemase (KPC) and Oxacillinase (OXA) carbapenemases. This project has been funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201600029C.
Cell Wall Synthesis Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Cell Wall Synthesis Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Cell Wall Synthesis Inhibitors
There are approx. 40+ key companies which are developing the therapies for Cell Wall Synthesis Inhibitors. The companies which have their Cell Wall Synthesis Inhibitors drug candidates in the most advanced stage, i.e. Phase III include, VenatoRx Pharmaceuticals.
Key Questions Answered
- How many companies are developing Cell Wall Synthesis Inhibitors drugs?
- How many Cell Wall Synthesis Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cell Wall Synthesis Inhibitors?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cell Wall Synthesis Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cell Wall Synthesis Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Spero Therapeutics
- VenatoRx Pharmaceuticals
- Recce Pharmaceuticals
Key Products
- Tebipenem HBr
- VNRX-7145
- Taniborbactam
- RECCE-327
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/jnc68q
